PharmaSGP Sees Strong Revenue Growth in 9M 2024, Raises Full-Year Forecast

PharmaSGP Holding SE, a German OTC pharmaceutical company, reported a robust revenue growth for the first nine months of 2024. Preliminary, unaudited figures reveal revenues of €88.6 million, marking a 17.0% increase from the previous year's €75.7 million. The third quarter alone brought in €30.2 million, sustaining the high performance exhibited earlier in the year. Adjusted EBITDA rose by 9.4% to €27.0 million, with a margin of 30.5%.

CEO Natalie Weigand attributed this success to effective marketing strategies and successful product launches, despite challenging macroeconomic conditions. CFO Michael Rudolf noted the company's dynamic revenue growth, leading to an updated revenue forecast for the full year of €112.0 to €117.0 million, up from the previous estimate of €107.0 to €112.0 million. The adjusted EBITDA projection remains between €35.0 and €38.0 million.